# A WORKFLOW DRIVEN PLATFORM SOLUTION FOR MAM-BASED CRTICAL QUALITY ATTRIBUTE MONITORING OF BIOTHERAPEUTICS **IN PROCESS DEVELOPMENT AND QC**

Nilini S Ranbaduge, Ying Qing, Min Du, Weibin Chen Waters Corporation, 34 Maple Street, Milford, MA 01757, USA

## INTRODUCTION

- Biotherapeutics undergo rigorous characterization and monitoring during development and production to maintain product quality and safety.
- Peptide-based monitoring is often used to monitor multiple attributes affecting the product quality.
- A compliance-ready, easy-to-use, high performance LC-MS system with automated methods is highly desired.
- The BioAccord is an SmartMS-enabled LC-MS system purposefully designed with integrated workflow methods for biopharmaceutical analyses including peptide-based quality attribute profiling and monitoring.




- Small foot print benchtop system • Easy-to-use & maintain
- cGMP compliance-ready

## **METHODS**


- Cone voltage: 30 V
- Collision energy: 60-120 V
- Desolvation energy: 350 °C
- Intelligent data capture: on
- Informatics: UNIFI Scientific Information v1.9.4 Peptide mapping method
  - Accurate mass screening method
  - UNIFI scientific library

## **End-to-end Workflow**

#### Sample preparation



#### Data processing



*Figure 1:* The end-to-end workflow for peptide attribute profiling and monitoring. The UNIFI processing methods are purposefully designed with automated data acquisition, processing and reporting capabilities.

## **METHODS**

#### Sample Preparation:

- The Trastuzumab (Genentech, USA) sample was subjected pH, heat and oxidative stress conditions as given below.
- Protein digestion: the intact mAb samples were digested with trypsin (Promega, Madison, USA) for 4 h at 37°C (20:1 protein to enzyme) following reduction, alkylation and buffer exchange steps. The samples were acidified and diluted prior to LC-MS analysis.

pH 9.0, at 37⁰C						
1 day  2 days		4 days	6 days			
Heat, 37°C						
4 d	lays	6 days				
H <sub>2</sub> O <sub>2</sub> , room temperature, 1 day						
0.0	05%	0.05%				


#### LC-MS System: BioAccord System

- Column: ACQUITY UPLC CSH C18, 1.7 μm, 2.1 x 100 mm
- Column temperature: 60 °C
- Mobile phase: A. 0.1% FA in water, B. 0.1% FA in Acetonitrile
- Total run Time: 80 min
- Sample temperature: 6 °C
- Injection volume: 5 µL
- Flow rate: 0.2 mL/min
- Gradient: 1%-35% Acetonitrile + 0.1% formic acid over 52 min
- Ionization: ESI+
- Acquisition mode: MS with fragmentation
- Acquisition range: *m/z* 50-2000
- Capillary voltage: 1.2 kV

## TO DOWNLOAD A COPY OF THIS POSTER, VISIT WWW.WATERS.COM/POSTERS

# RESULTS

## **Peptide Mapping Method**



#### (B) Identify peptides and their modifications

Con	Component Summary +								
	Protein name	Fragment label	Peptide	Modifiers	Observed RT (min)	Observed m/z	Charge	Observed mass (Da)	Mass error
29	TmAb	2:T9	FTISADTSK		13.6	485.2478	2	969.4883	
30	TmAb	2:T37	GFYPSDIAVEWESNGQPENNYK		30.1	848.7169	3	2544.1361	
31	TmAb	2:T5	GLEWVAR		17.9	415.7302	2	830.4531	
32	TmAb	2:T13	GPSVFPLAPSSK		22.8	5 593.8281	2	1186.6489	
33	TmAb	2:T6	IYPTNGYTR		11.5	542.7746	2	1084.5419	
34	TmAb	2:T6&	IYPTNGYTR	Deamidation N [5]	12.8	543.2662	2	1085.5251	
35	TmAb	2:T6&	IYPTNGYTR	Deamidation N [5]	13.2	543.2679	2	1085.5285	
36	TmAb	1:T5	LLIYSASFLYSGVPSR		34.4	2 591.6587	3	1772.9617	
37	TmAb	2:T2&	LSCAASGFNIK	Carbamidomethyl C [3]	17.24	584.2964	2	1167.5856	
38	TmAb	2:T39	LTVDK		5.1	288.1736	2	575.3399	
39	TmAb	2:T36&	NQVSLTCLVK	Carbamidomethyl C [7]	21.6	2 581.3192	2	1161.6311	
10	TmAb	2:T36&	NQVSLTCLVK	Carbamidomethyl C [7], Deamidation N [1]	24.3	581.8081	2	1162.6089	

#### Custom attribute library Sequence & modifications

Mass & retention time

Limit check capability


Detected charge states, etc.

## **Peptide Attribute Monitoring**

#### (A) Target peptide attribute list


	target criteria									
Manag	Manage Components									
Create	Create Import Paste Results Delete Edit Fragments Edit Adducts Add To Common Fragments Add To Neutral Losses									
1	Component name	Label	Expected RT (min)	Expected neutral mass (Da) 1 -	Expected fragment (m/z)	Adducts	Description	Internal standard?		
1	YGGFL	YGGFL	22.67	555.2693			1:T1+H <sup>*</sup> - LeuEnk			
2	SLSLSPGK -Lysine C-TERM	SLSLSPGK	17.61	659.3490			2:T42&:-Lysine C-TERM [8]+H* - TmAb			
3	SLSLSPGK	SLSLSPGK	12.22	787.4440			2:T42+H* - TmAb			
4	DTLMISR	DTLMISR	15.44	834.4269			2:T21+H* - TmAb			
5	DTLMISR Oxidation M	DTLMISR	12.70	850.4219			2:T21&:Oxidation M [4]+H* - TmAb			
6	IYPTNGYTR	IYPTNGYTR	11.56	1083.5349			2:T6+H* - TmAb			
7	IYPTNGYTR Deamidation N	IYPTNGYTR	12.83	1084.5189			2:T6&:Deamidation N [5]+H* - TmAb			
8	IYPTNGYTR Deamidation N_1	IYPTNGYTR	13.20	1084.5189			2:T6&:Deamidation N [5]+H* - TmAb			
9	NTAYLQMNSLR	NTAYLQMNSLR	19.87	1309.6449			2:T10+H* - TmAb			
10	NTAYLQMNSLR Deamidation N	NTAYLQMNSLR	21.23	1310.6289			2:T10&:Deamidation N [8]+H* - TmAb			
11	NTAYLQMNSLR Deamidation N_1	NTAYLQMNSLR	20.41	1310.6289			2:T10&:Deamidation N [8]+H* - TmAb			
					-					

#### Accurate mass screening-based detection and quantification




*Figure 3:* (A) The target peptide list is imported from custom attribute library created using peptide mapping results. Each library entry contains peptide sequence, neutral mass and retention time information (and fragment ions). Both neutral mass and retention time are used to identify peptide CQAs in the accurate mass screening method. (B) The XICs of target peptides (native and modified) are extracted for the monoisotopic masses or multiple isotopes. The peak area of each XIC is used to generate relative %modifications. (C) The summary plot shows native and deamidated IYPTNGYTR peptide %modification levels across samples. Each relative modification level is determined based on the total MS response for the respective peptide sequence.

#### (A) Node Field name Component Component %Peptide Mod-MS (%) DTLMISR Oxidation M Component %Peptide Mod-MS (%) IVPTNGYTR Deamidation N, IVPTNGYTR Deamidation N 1 All Selected limit graphic representati (B) Exceed error limits Component: IYPTNGYTR Deamidation N 23.7 23.6 Exceed warning 13.0 12.8 9.3 9.0 9.0 $\longleftrightarrow$ pH stress (pH 9.0) control



*Figure 5:* Comparison mode feature compares sample to its reference/control. This figure shows a chromatographic comparison of Trastuzumab control and a pH stressed sample. Specific data filters are applied to isolate unique peptide peaks or peptides present at a higher level (>5-fold) in the stress sample compared to the control.

# THE SCIENCE OF WHAT'S POSSIBLE.



#### (C) Sequence confirmation using fragment ions





Figure 2: (A) The peptides and their modifications are chromatographically separated prior to MS analysis. This figure shows the total ion chromatogram of one of the pH stressed samples. (B) The component table provides all identified peptide sequences and modifications with their respective retention times, mass tolerance, *m/z*, number of primary fragment ions, etc. (C) The figure shows annotated fragment ion spectra for native and modified IYPTNGYTR. The fragmentation information is used in data filtering for high confidence peptide attribute identification.



*Figure 4:* (A) The limits can be applied during data processing by introducing upper/lower thresholds. (B) The limits are used for easy visualization of data that flags both samples and attribute in a preset color. In here, yellow and red display warning and error limits of an attribute respectively.

### Comparable quantification data obtained with and without fragmentation




Figure 6: When performed in MS only mode % modification level for an attribute provides comparable results to that of the MS with fragmentation mode. This allows the user to chose either method in routine peptide attribute monitoring.

## CONCLUSION

- The BioAccord is a compact LC-MS system that can be easily deployed across biopharmaceutical organizations from discovery thru QC.
- Integrated workflows (UNIFI Informatics) for intact protein, released-glycan and peptide analysis support automated attribute screening and monitoring workflows.
- Accessibility to non MS experts is facilitated by one-button startup, intelligent diagnostics, and automated tuning/calibration routines.
- Information transfer between peptide characterization and monitoring workflows is enabled by the UNIFI scientific library functionality, allowing lists of attributes to be incrementally updated for later use in targeted monitoring analyses.
- Automated data acquisition, processing, review, reporting, and signoff streamlines operations within regulated laboratories where data integrity is a concern.
- The ability to automatically highlight product attributes exceeding warning or error limits and denote new data features (potential attributes) vs. a reference sample greatly simplifies review and reporting of multiple attribute monitoring (MAM) studies.